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Abstract
Cholangiocarcinoma is a relatively rare form of gastroenterological cancer that divided 
into intrahepatic, perihilar, and distal bile duct cancer. Approximately, 10,000 new cases 
are diagnosed annually in the United States, and a 5-year survival rate is below 20%. While 
only surgical resection can provide a cure, most of cholangiocarcinomas are detected 
at inoperable stage and associated with poor prognosis. Moreover, cholangiocarcinoma 
has a high recurrence rate, even after curative surgery. Therefore, chemotherapy has an 
important role in the treatment of patients with cholangiocarcinoma. International efforts 
by physicians and researchers are revealing genetic factors of cholangiocarcinoma pro-
gression, which will identify early diagnostic markers and novel therapeutic targets. In 
this chapter, current strategies of adjuvant, neoadjuvant, and palliative chemotherapy 
will be discussed, as well as expectant future therapeutic targets and development of 
individualized therapies.
Keywords: cholangiocarcinoma, biliary tract cancer, biliary tract neoplasms, 
chemotherapy, precision medicine
1. Introduction
Cholangiocarcinoma is a rare malignant tumor that originates from the epithelial cells of 
the bile duct system. About 90% of cholangiocarcinoma are adenocarcinoma and divided 
into three forms based on histologic growth pattern as mass-forming, periductal-infiltrating, 
and intraductal-growing [1]. Generally, cholangiocarcinoma can be divided by anatomical 
location of biliary tree, as intrahepatic cholangiocarcinoma and extrahepatic cholangiocar-
cinoma including perihilar cholangiocarcinoma and distal bile duct cancer. Extrahepatic 
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cholangiocarcinoma is a more common form of cholangiocarcinoma, comprising approxi-
mately 80–90% of cholangiocarcinoma. Extrahepatic cholangiocarcinoma consists of peri-
hilar cholangiocarcinoma and distal bile duct cancer. Perihilar cholangiocarcinoma, also 
called Klatskin tumor, is the most common type, accounting for approximately 50–60% of 
all cases, and can be defined as a tumor located above the junction of the cystic duct up to 
and including the second-order biliary branches of the right and left bile ducts [2]. Distal 
cholangiocarcinoma arose from distal biliary tract above the ampulla of Vater, accounting 
or approximately 20–30% of all cholangiocarcinoma. Intrahepatic cholangiocarcinoma is in 
liver parenchyma, accounting for 10–20% of cholangiocarcinoma.
Approximately 10,000 new cases are diagnosed annually in the United States, and 5-year 
survival rate is below 20% [3]. In Korea, there are 11.2 new cases per 100,000 people annually, 
and a 5-year survival rate is 29.2% according to cancer statics in 2014 [4]. While only surgical 
resection can provide a cure, most of cholangiocarcinomas are detected at inoperable stage 
and associated with poor prognosis. Moreover, cholangiocarcinoma has high recurrence rate, 
even after curative surgery [5]. Therefore, chemotherapy has an important role in the treat-
ment of patients with cholangiocarcinoma. However, there are only few therapeutic options 
that establish an effective chemotherapy for advanced cholangiocarcinoma. International 
efforts by physicians and researchers are revealing genetic factors of cholangiocarcinoma pro-
gression, which will identify early diagnostic markers and novel therapeutic targets.
In this chapter, current strategies of adjuvant, neoadjuvant, and palliative chemotherapy will 
be discussed as well as expectant future therapeutic targets and development of individual-
ized therapies.
2. Adjuvant chemotherapy
2.1. Necessity of adjuvant chemotherapy
Necessity of adjuvant chemotherapy for cholangiocarcinoma is based on prognosis after sur-
gical treatments. Surgery is only curative therapy of cholangiocarcinoma; however, a 2-year 
survival of cholangiocarcinoma after curative aim surgery was reported very poor. According 
to a prospective study of 225 patients with hilar cholangiocarcinoma, 80 patients underwent 
resection, and 48.8% died of disease by 28 months [6]. In this situation, selection of high-risk 
patients for recurrence after surgery became important. Due to anatomical heterogeneity of 
cholangiocarcinoma and proximity to other organs, many of previous studies were including 
cancers originated from the gallbladder or ampulla of Vater as well as intrahepatic and extra-
hepatic cholangiocarcinoma. Long-term outcomes of curative surgery of cholangiocarcinoma 
are various according to postoperative stage including nodal status, anatomical location, and 
histologic margin status. Despite of native difficulties of research about cholangiocarcinoma, 
the most important conditions proven by previous studies are nodal involvements and histo-
logic margin status after surgery.
A couple of retrospective studies reported postoperative nodal status that is a significant prog-
nostic factor after surgery of extrahepatic cholangiocarcinoma. About 104 patients with distal 
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bile duct tumors were identified by prospective database. By univariate and multivariate analy-
sis, resectability and negative node status (P < 0.001) were the only predictors of favorable out-
come [7]. A retrospective single-center experience details of 151 patients after surgical resection 
of central bile duct carcinoma reported only lymph node metastases, and residual tumor stage 
proved to be of independent prognostic significance in a multivariate Cox analysis [8]. Another 
retrospective study of 46 patients who had resection of hilar cholangiocarcinoma by major 
hepatectomy, bile duct resection, and regional lymphadenectomy reported R0 resection and 
lymph node metastasis were associated with survival [9]. According to a retrospective study of 
320 patients with perihilar cholangiocarcinoma who underwent resection, upon multivariate 
analysis of the 146 patients with lymph node metastasis, the number of involved nodes (single 
versus multiple) was identified as an independent prognostic factor (RR of 1.61, P = 0.045) [10].
There were studies reported that nodal status was also important in intrahepatic cholan-
giocarcinoma. About 93 patients who underwent laparotomy for ICC were identified retro-
spectively, and 46 who underwent curative resection and systematic lymphadenectomy. An 
increased ratio of positive to total harvested lymph nodes was prognostic for adverse outcome 
in lymph node-positive patients [11]. In a total of 60 liver resections for mass-forming-type 
intrahepatic cholangiocarcinoma, the lymphatic invasion index and histological grade were 
statistically independent prognostic factors for overall survival and recurrence-free survival 
in multivariate analysis [12].
Resection margin status was also reported as strong independent prognostic factor after 
surgery in cholangiocarcinoma. In a retrospective analysis of 84 patients with extrahepatic 
cholangiocarcinoma who underwent surgical resection, ductal resection margin status was 
classified as negative (n = 64 patients), positive with carcinoma in situ (n = 11 patients), 
or positive with invasive carcinoma (n = 9 patients). The ductal margin status was found 
to be a strong independent prognostic factor by both univariate (P = 0.0002) and multivari-
ate (P = 0.0039) analyses [13]. In 109 patients with resected perihilar tumors, the 1-, 3-, and 
5-year survival was 68, 30 and 11%, respectively. The median survival was 19 months. The 
addition of hepatic lobectomy did not alter the survival rate. Negative margins and negative 
lymph node status were associated with improved survival [14]. In a prospective study of 
225 patients with hilar cholangiocarcinoma, 80 patients underwent resection, and 62 patients 
showed R0 resection. In the 219 patients whose disease could be staged, the proposed system 
predicted resectability and the likelihood of an R0 resection and correlated with metastatic 
disease and survival [6]. In a prospective study of 27 patients with cholangiocarcinoma at 
the confluence of the hepatic ducts who underwent resection, the difference in survival times 
between patients with histologic clearance and those with microscopically positive or close 
(less than 1 mm) resection margins was significant statistically (P = 0.037) [15].
In addition, lymphovascular and perineural invasion and large tumor size have been reported 
as independent predictors of recurrence and reduced overall survival after surgical resec-
tion of intrahepatic cholangiocarcinoma [16, 17]. It might be confusing to analyze the stud-
ies of bile duct cancers that originate in various locations. However, plenty of studies above 
reported that marginal resection and lymph node involvement status are significantly associ-
ated with surgical outcomes and patient survival. To improve survival of patients after surgi-
cal resection, studies of adjuvant chemotherapy were performed.
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2.2. Indication and efficacy of adjuvant chemotherapy
Cholangiocarcinoma has various subtypes according to anatomical location, and most of 
the studies about adjuvant chemotherapy contain patients with gallbladder cancer, ampulla 
of Vater cancer, or pancreatic cancer. In addition to heterogeneity of the origin of cancers, 
regimen of chemotherapies and disease status such as post-op stage including lymph node 
involvement or margin status are also various. Majority of previous studies were retrospec-
tive design, except one phase III trial that had not shown a significant outcome improvement 
after adjuvant chemotherapy.
Several studies were performed to evaluated efficacy of adjuvant chemotherapy for cholangio-
carcinoma, and the results were controversial. A retrospective study reported that the benefit 
of adjuvant chemotherapy after surgery in cholangiocarcinoma is questionable. According to 
the study including gallbladder cancer and cholangiocarcinoma, of the 157 patients, 17.8% 
received neoadjuvant chemotherapy, and 48.7% received adjuvant chemotherapy, while 15.8% 
received adjuvant chemoradiotherapy. Patients with negative margins of at least 1 cm had a 
5-year survival rate of 52.4% (P < 0.01). Adjuvant therapy did not significantly prolong sur-
vival in 94 patients with cholangiocarcinoma [18]. There were other studies that provide posi-
tive evidence of adjuvant chemotherapy of cholangiocarcinoma. A retrospective review of 115 
patients with hilar cholangiocarcinoma and patients treated with chemotherapy postopera-
tively had a survival of 43.15 ± 21.02 months, which was significantly longer than the survival 
of patients who received no postoperatively chemotherapy (36.97 ± 15.99 months; P < 0.05) [19].
A systematic review and meta-analysis about adjuvant chemotherapy of cholangiocarcinoma 
and gallbladder cancer supported adjuvant chemotherapy for biliary tract cancer. About 20 
studies involving 6712 patients were analyzed in the study. Among the 20 studies, there were 
1 randomized trial of chemotherapy alone, 2 registry analyses, and 17 institutional series. In 
the overall population, pooled data showed a nonsignificant improvement in survival with 
any adjuvant therapy compared with surgery alone (OR, 0.74; P = 0.06, and for bile duct 
cancers OR, 0.71; P = 0.10). However, after the two registry analyses were excluded, receiv-
ing chemotherapy demonstrated statistically greater benefit than surgery alone (P = 0.02). In 
subgroup analysis, the greatest benefit for adjuvant therapy was in those with lymph node-
positive disease (OR, 0.49; P = 0.004) and R1 disease (OR, 0.36; P = 0.002) [20].
About the chemotherapy regimen, there is only one phase III randomized controlled studies 
that had proven limited survival benefit. A phase III randomized trial of adjuvant chemother-
apy of cholangiocarcinoma, the European Study Group for Pancreatic Cancer (ESPAC)-3 peri-
ampullary trial, was performed in 100 centers in Europe, Australia, Japan, and Canada. Of the 
428 patients included in the primary analysis, 297 had ampullary, 96 had bile duct, and 35 had 
other cancers. About 144 patients were assigned to the observation group, 143 patients received 
fluorouracil chemotherapy, and the other 141 patients received gemcitabine chemotherapy. 
Median survival for the observation group was 35.2 months, for patients treated with fluoro-
uracil plus folinic acid 38.9 months, and for patients treated with gemcitabine 45.7 months. 
The hazard ratio (HR) for fluorouracil plus folinic acid versus observation was 0.95 (P = 0.74), 
and for gemcitabine versus observation, 0.77 (P = 0.10), not significant by log-rank analysis 
across the three groups (P = 0.23). In secondary analyses adjusting for prognostic variables 
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using multiple regression analysis, the HR for chemotherapy compared with observation 
was 0.75 (P = 0.03) and for gemcitabine 0.70 (P = 0.03). Conclusively, adjuvant chemotherapy 
was not associated with a significant survival benefit in the primary analysis compared with 
observation; however, multivariate analysis adjusting compounding factors showed survival 
benefits associated with adjuvant chemotherapy, especially with gemcitabine [21].
According to the results of the meta-analysis and ESPAC-3 trail, adjuvant chemotherapy is 
effective in patients with cholangiocarcinoma after curative surgery, especially with lymph 
node-positive and resection margin-positive disease.
2.3. Guideline recommendation for adjuvant chemotherapy
There were two guidelines about adjuvant chemotherapy of cholangiocarcinoma by expert 
groups.
The National Comprehensive Cancer Network (NCCN) suggests adjuvant chemotherapy 
after curative surgery of cholangiocarcinoma and regimens according to lymph node and 
margin status [22]. Although there are limited clinical trial data to establish a standard 
chemotherapy regimen for intrahepatic cholangiocarcinoma after surgery, recommended 
regimens based on fluoropyrimidine or gemcitabine chemotherapy. In patients with no 
residual local disease (R0) resection, observation or clinical trial can be a choice with fluoro-
pyrimidine-based or gemcitabine-based chemotherapy. If the patients have a disease with 
microscopic margin positive (R1) or positive regional lymph nodes, chemotherapy is rec-
ommended than observation. In addition to fluoropyrimidine-based or gemcitabine-based 
chemotherapy, clinical trial or fluoropyrimidine chemoradiation can be a treatment option. 
In spite of receiving curative surgery, patients may have residual local disease. In this situ-
ation, clinical trial, locoregional therapy such as transarterial chemoembolization, or best 
supportive care is included as options with chemotherapy with gemcitabine or fluoropy-
rimidine. NCCN guideline for adjuvant chemotherapy of extrahepatic cholangiocarcinoma 
is also based on fluoropyrimidine-based or gemcitabine-based chemotherapy. However, 
there are limited clinical trial data to set a standard therapy. If available, enrollment in 
a clinical trial is encouraged. If the disease had negative margin or carcinoma in situ at 
margin without regional nodes, observation, fluoropyrimidine chemoradiation, fluoropy-
rimidine−/gemcitabine-based chemotherapy, or clinical trial is recommended as treatment 
options. If patients had positive margin (R1 or R2) or positive regional nodes, fluoropy-
rimidine chemoradiation followed by additional fluoropyrimidine-based or gemcitabine-
based chemotherapy can be considered, as well as fluoropyrimidine−/gemcitabine-based 
chemotherapy or clinical trial.
The European Society of Medical Oncology (ESMO) clinical practice guidelines for biliary 
cancer suggest adjuvant chemotherapy for intrahepatic and extrahepatic cholangiocarcinoma 
after curative aim surgery [23]. ESMO recommendations offer adjuvant therapy to patients 
on the understanding that the evidence base is weak and encourage enrollment in clinical 
trials. When the results from previous meta-analysis were employed, chemoradiation is rec-
ommended with 45 Gy dose of radiotherapy in fractions of 1.8 or 2 Gy with concurrent 5-fluo-
rouracil or capecitabine [IV, C].




There are not enough evidences about neoadjuvant chemotherapy of cholangiocarcinoma. 
In a retrospective study including gallbladder cancer and cholangiocarcinoma, neoadjuvant 
therapy delayed surgical resection on average for 6.8 months (p < 0.0001). Immediate resec-
tion increased median survival from 42.3 to 53.5 months (p = 0.01) [18]. A couple of reports 
addressed possibility to use neoadjuvant chemoradiation before liver transplantation in 
patients with cholangiocarcinoma [24–28]. In a study of 287 patients with perihilar cholangio-
carcinoma using neoadjuvant therapy, 71 patients dropped out before liver transplantation 
(rate, 11.5% in 3 months). Intent-to-treat survival rates were 68 and 53%, 2 and 5 years after 
therapy, respectively; posttransplant recurrence-free survival rates were 78 and 65%, respec-
tively [25]. In a retrospective study of patients with hilar cholangiocarcinoma, 71 patients 
entered in the protocol combining neoadjuvant radiotherapy, chemosensitization, and ortho-
topic liver transplantation. About 38 patients underwent liver transplantation, and 26 (48%) 
underwent resection One-, 3-, and 5-year patient survivals were 92, 82, and 82% after trans-
plantation and 82, 48, and 21% after resection (P = 0.022) [27]. Of the 57 patients with intra-
hepatic and hilar cholangiocarcinoma, neoadjuvant and adjuvant therapies resulted in better 
patient survival after liver transplantation compared with no therapy or adjuvant therapy 
only (47% versus 20% versus 33%, respectively; P = 0.03) [28]. Despite the lack of result from 
randomized controlled trial, neoadjuvant chemoradiation might be one of treatment options 
in selected patients with hilar cholangiocarcinoma before liver transplantation. Further pro-
spective trials are needed in large population for establish neoadjuvant therapy as a reliable 
therapeutic option in cholangiocarcinoma.
4. Palliative chemotherapy
Palliative chemotherapy has an important role in the treatment of advanced and recurrent 
cholangiocarcinoma. The current standard therapy for patients with inoperable cholangiocar-
cinoma is a combination of gemcitabine and cisplatin chemotherapy. A previous randomized 
controlled trial revealed that combining gemcitabine with cisplatin improved the overall sur-
vival by 3.6 months compared to gemcitabine alone [29]. According to the study, gemcitabine 
with cisplatin combination became the standard therapy of advanced and metastatic chol-
angiocarcinoma. However, there is no established second-line palliative chemotherapy that 
could be used after failure of gemcitabine-based chemotherapy. Moreover, cisplatin is associ-
ated with severe toxicity, including dose-dependent nephrotoxicity and neurotoxicity, which 
may limit the opportunities for second-line treatment after disease progression.
4.1. First-line chemotherapy
Benefits of chemotherapy for advanced biliary tract cancer were reported by various studies. 
In a phase III trial of patients with 53 pancreatic cancer and 37 biliary tract cancer, patients 
were randomized to a chemotherapy group in addition to the best supportive care or to the 
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best supportive care group. Chemotherapy was either sequential 5-fluorouracil/leucovorin 
combined with etoposide or in elderly and poor performance patients, the same regimen with-
out etoposide. Overall survival was significantly longer in the chemotherapy group (median 
6 versus 2.5 months, P < 0.01) [30]. A pooled analysis of clinical trials reported analysis of the 
effect of chemotherapy in advanced biliary tract cancer. The study included 104 trials with 
2810 patients, thereof 634 responders and 1368 patients with tumor control. Superior response 
rates and tumor control rates of gemcitabine and platinum-containing regimens were found 
in the results [31]. A multicenter retrospective study showed that patients receiving gem-
citabine had a benefit in survival compared to cisplatin-based regimen or fluoropyrimidine-
based regimen or the best supportive care in 304 patients with advanced biliary tract cancer 
[32]. Upon a base of the results of the previous studies about the efficacy of the first-line che-
motherapy for advanced cholangiocarcinoma, a lot of phase II studies were tried to evaluate 
therapeutic efficacy of combination chemotherapy in advanced cholangiocarcinoma.
4.1.1. Fluoropyrimidine-based combination therapies
Several studies evaluated fluoropyrimidine-based combination therapies. A randomized 
phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in 
patients with 58 advanced biliary tract carcinoma reported similar response rate, progression-
free survival, and overall survival [33]. Another phase II trial in 42 patients with advanced 
biliary tract carcinoma reported 5-fluorourasil continuous infusion, and low-dose consecutive 
cisplatin therapy appeared to be a useful modality with over all response rates (42.9%) and 
median survival time (225 days) [34].
4.1.2. Gemcitabine-based combination therapies
A couple of gemcitabine-based combination therapies were tried in advanced cholangiocarci-
noma. One randomized phase II trial compared mitomycin C in combination with capecitabine 
or biweekly high-dose gemcitabine in patients with 51 advanced biliary tract cancer. As a result, 
mitomycin C in combination with capecitabine seems to be superior in terms of response rate 
(31 versus 20%), progression-free survival (5.3 versus 4.2 months), and overall survival (9.25 
versus 6.7 months) [35]. Gemcitabine with oxaliplatin combination therapy was tried in phase 
II trials [36–38]. These studies demonstrated moderate efficacy and tolerability. In one of 
the studies of 70 patients with advanced biliary tract cancer, the objective response rate was 
20.5% in non-bladder biliary tract cancers [37]. Combination of capecitabine with gemcitabine 
therapy demonstrated active and well-tolerated performance as first-line chemotherapy for 
advanced biliary cancer [39–41]. In a phase II trial, a total of 44 patients received a combination 
of capecitabine with gemcitabine as first-line therapy and reported median time to disease 
progression of 6 months and overall survival of 14.0 months [39]. In another phase II trial, 
capecitabine plus cisplatin combination was reported as well-tolerated regimen for advanced 
biliary cancer [42]. Some of the study groups reported trials of gemcitabine- and 5-fluorouracil-
based combination therapy [43, 44]. With 42 advanced biliary tract cancer patients, a combina-
tion of gemcitabine, 5-fluorouracil (5-FU), and leucovorin (LV) demonstrated median time to 
disease progression as 4.6 months and median survival period as 9.7 months [43].
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Triplet chemoregimen also has been tried as first-line chemotherapy for advanced diseases 
[44–46]. A phase III study of 5-FU, etoposide, and leucovorin (FELV) compared to epirubicin, 
cisplatin, and 5FU (ECF) was tried in patients with advanced biliary tract cancer. The median 
overall survival for ECF was 9.02 months and FELV 12.03 months (p = 0.2059) in 54 patients 
randomly assigned to each arm. Objective response rates were similar for both arms (ECF 
19.2% versus FELV 15%, p = 0.72). However, grade 3/4 neutropenia was significantly increased 
with FELV versus ECF (53.8 versus 29.5%, P = 0.020). In conclusion, ECF did not improve OS 
compared to FELV, but was associated with less acute toxicity [45].
4.1.3. Gemcitabine with cisplatin combination therapy
Among gemcitabine-based chemotherapy combination, there were several studies of gem-
citabine plus cisplatin combination. These studies evaluated efficacy and safety of gemcitabine 
plus cisplatin combination with one-armed phase II trial, and they reported potent efficacy 
and good tolerability of this combination [47–49]. A randomized phase II trial, the advanced 
biliary cancer (ABC)-01 trial, had found gemcitabine with cisplatin combination associated 
with an improved tumor control rate, 6 months of progression-free survival (47.7–57.1%) com-
pared to gemcitabine alone in 86 patients with advanced cholangiocarcinoma [50]. ABC-01 
trial was extended to a phase III trial, the ABC-02 trail, and the study results were published 
in 2010. A total of 410 patients with locally advanced or metastatic cholangiocarcinoma, gall-
bladder cancer, or ampullary cancer were randomly assigned to either cisplatin followed by 
gemcitabine or gemcitabine alone. The median overall survival was 11.7 months in the cispla-
tin-gemcitabine group and 8.1 months among the gemcitabine group (P < 0.001). The median 
progression survival (8.0 versus 5.0 months, P < 0.001) and tumor control rate (81.4 versus 
71.8%, p = 0.049) were improved in cisplatin-gemcitabine group. Adverse events were similar 
in the two groups, with the exception of more neutropenia in the cisplatin-gemcitabine group 
[29]. After ABC-02 trial, another study of 84 patients with advanced cholangiocarcinoma also 
reported that cisplatin-gemcitabine combination showed better survival rate and survival time 
compared to gemcitabine alone [51].
According to the results of ABC-02 trial, gemcitabine plus cisplatin combination became 
the standard treatment option for first-line chemotherapy for advanced and metastatic 
cholangiocarcinoma.
4.1.4. Target agents
In addition to combination of cytotoxic chemotherapy agents, combination regimen with tar-
get agents was studied in several phase II trials.
A couple of studies evaluated a possibility of epidermal growth factor receptor (EGFR) 
inhibitors as combination agent with conventional chemotherapeutic agents. A phase II trial 
of gemcitabine, irinotecan, and panitumumab in advanced cholangiocarcinoma demon-
strated the median progression-free survival as 9.7 months and the median overall survival 
as 12.9 months in 35 patients [52]. Another EGFR-targeted monoclonal antibody, cetuximab, 
was tried in phase II studies. In 30 patients with advanced biliary tract cancer, cetuximab, 
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gemcitabine, and oxaliplatin combination demonstrated 63% of objective response rate (10% 
of complete response and 53% of partial response) [53]. Because of the promising results of 
this study, the addition of cetuximab to gemcitabine and oxaliplatin did not seem to enhance 
the activity of chemotherapy in patients with advanced biliary cancer in the randomized 
phase II BINGO study. In the study, 76 patients were assigned to chemotherapy plus cetux-
imab and 74 to chemotherapy alone. The median progression-free survival was 6.1 versus 
5.5 months, and the medial overall survival was 11.0 versus 12.4 months in chemotherapy 
plus cetuximab and chemotherapy alone group, respectively [54].
Another phase II study tried the application of sorafenib, an oral multi-tyrosine kinase inhibi-
tor, with gemcitabine. Gemcitabine plus sorafenib versus gemcitabine alone was compared 
in advanced biliary tract cancer, and there was no difference in the median progression-free 
survival for gemcitabine plus sorafenib versus gemcitabine alone (3.0 versus 4.9 months, 
P = 0.859) and no difference for median overall survival (8.4 versus 11.2 months, P = 0.775). In 
conclusion, the addition of sorafenib to gemcitabine did not demonstrate improved efficacy 
in advanced biliary tract cancer patients [55].
Cediranib, an oral inhibitor of VEGF receptors 1, 2, and 3, was evaluated in combination with 
cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer by a 
randomized phase II trial. As a result, cediranib did not improve the progression-free survival 
of patients with advanced biliary tract cancer in combination with cisplatin and gemcitabine 
compared to placebo (8.0 versus 7.4 months, p = 0.72) [56].
With the results described above, there was not enough evidence to use target agents in 
advanced cholangiocarcinoma, and further study seems to be needed.
4.2. Second-line chemotherapy
There was not enough evidence about efficacy of second-line chemotherapy for advanced 
chemotherapy. In a systematic review of second-line chemotherapy in advanced biliary can-
cer including 25 studies, 14 phase II clinical trials, 9 retrospective analyses, and 2 case reports 
evaluate the level of evidence for the use of second-line chemotherapy. A total of 761 patients 
were evaluated, the mean OS was 7.2 months, and the mean progression-free survival, and 
response and disease control rates were 3.2 months and 7.7 and 49.5%, respectively. In con-
clusion, there is insufficient evidence to recommend a second-line chemotherapy schedule in 
advanced biliary tract cancer [57]. Still, the efficacy of second-line chemotherapy for advanced 
cholangiocarcinoma is not definite. Further prospective randomized trials are needed to 
develop evidence of second-line chemotherapy for advanced cholangiocarcinoma.
4.3. Guideline recommendation for palliative chemotherapy
The National Comprehensive Cancer Network (NCCN) and the European Society of Medical 
Oncology (ESMO) suggest guidelines for chemotherapy in advanced biliary tract cancer.
NCCN guidelines recommend gemcitabine and cisplatin combination therapy as first-line 
chemotherapy with a category 1 recommendation for patients with advanced biliary tract 
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cancer [22]. Gemcitabine-based and fluoropyrimidine-based combination chemotherapies 
are other options with a category 2A recommendation. Based on the results of phase II tri-
als, gemcitabine with oxaliplatin or capecitabine; capecitabine with cisplatin or oxaliplatin; 
fluorouracil with cisplatin or oxaliplatin; and single-agent fluorouracil, capecitabine, and 
gemcitabine are included. Second-line chemotherapy is not recommended due to insufficient 
evidence of the efficacy. In unresectable but nonmetastatic disease, fluoropyrimidine chemo-
radiation can be another option. In addition, patients with intrahepatic cholangiocarcinoma, 
locoregional therapy such as external beam radiotherapy, and arterially directed therapy can 
be tried with a category 2B recommendation.
ESMO clinical practice guidelines suggest a combination therapy for performance score 
(PS) 0–1 patients and monotherapy for PS 2 patients with advanced cholangiocarcinoma 
[23]. According to the guidelines, cisplatin/gemcitabine is the reference regimen for good PS 
patients, and oxaliplatin may be substituted for cisplatin with concern about renal function. 
For PS 2 patients, gemcitabine monotherapy may be considered. And, second-line chemother-
apy and targeted therapies are not recommended due to lack of evidence. Radiotherapy may 




Personalized therapy is noticed in recent periods including target therapy and immuno-
therapy, in addition to systemic chemotherapy or chemoradiation for cholangiocarcinoma. 
Understanding of the molecular pathways associated with development and progression of 
cholangiocarcinoma may help identify novel biomarkers and develop potential therapeutic 
targets. On the basis of the development of gene sequencing technic, it is expected that precise 
medicine will be possible by judging the presence or absence of a specific gene expressed in a 
patient and selecting a therapeutic drug according to gene expression.
So far, most of previous studies have studied cholangiocarcinoma and gallbladder cancer 
as a group of biliary tract cancers; however, recent studies revealed that molecular profiling 
of cholangiocarcinoma is different from gallbladder cancer. Furthermore, several studies 
reported that intrahepatic and extrahepatic cholangiocarcinomas have different molecu-
lar features. Jusakul et al. reported the research combining whole-genome sequencing and 
epigenomic analysis of cholangiocarcinoma with 489 patients from 10 countries [58]. In the 
study, cholangiocarcinoma was subgrouped into four clusters according to their molecular 
features. Cluster 1 comprised mostly fluke positive tumors with enrichment of ARID1A 
and BRCA1/BRCA2 mutations. Cluster 2 was characterized by a mix of fluke positive and 
negative tumors with upregulated CTNNB1, WNT5B, and NKT1. Clusters 1 and 2 were 
enriched in TP53 mutation and ERBB2 gene expression. Clusters 3 and 4 were mostly fluke 
negative tumors, and cluster 3 exhibited specific upregulation of immune checkpoint genes, 
PD-1, PD-L2, and BTLA. Cluster 4 had BAP1, IDH1/2 mutations, and FGFR alterations. 
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Anatomical classification of cholangiocarcinoma was associated with clusters. Clusters 1 
and 2 were enriched in extrahepatic tumors, whereas clusters 3 and 4 consisted almost 
of intrahepatic tumors. Moreover, intrahepatic cholangiocarcinoma was more frequently 
mutated in BAP1 and KRAS. Clinically, each clusters had different overall survivals; clus-
ters 3 and 4 had significantly better overall survival than clusters 1 and 2. These findings 
suggest that heterogenic clinical features of cholangiocarcinoma were also based on genetic 
and epigenetic variance of tumors, and further studies have to focus on classifying sub-
groups according to treatment strategy and identifying novel therapeutic targets for per-
sonalized therapy.
5.2. Identifying novel biomarkers as therapeutic targets
To establish reliable strategy for precision medicine, it is important to identify novel molecu-
lar pathways and develop them as therapeutic targets. Recent studies developed growth fac-
tor receptors and signaling pathways as targets of cholangiocarcinoma. As mentioned above, 
the EGFR/VEGF inhibitors and multi-kinase inhibitors have been evaluated to be treatment 
options. Other promising signaling pathways associated with cholangiocarcinoma, such as 
RAS/RAF/MEK and PI3K/AKT/mTOR pathways, are also being studied to be another candi-
date of target agents. Clinical trials and researches are needed to find new target and evaluate 
efficacy of novel target agents. Big data analysis and artificial intelligence technologies are 
expected to reduce the time and effort required to set new molecular targets.
5.3. Immunotherapy
Advances in knowledge of cancer immunology provide opportunity of immunotherapy as 
a new therapeutic option for cholangiocarcinoma. Immunotherapy strengthens the immune 
system of patients to struggle against cancer by the concept of personalized vaccination, 
adoptive immunotherapy, or immune checkpoint inhibitor therapy. One of the immune 
checkpoint inhibitors, pembrolizumab, which is a blocker of programmed cell death 1 (PD-
1) pathway and its ligands (PD-L1 and PD-L2), has been reported as a possible promising 
antitumor agent in patients with advanced biliary tract cancer in the interim results of the 
clinical trial, KEYNOTE-028. In the study, objective response rate was 17% (four has partial 
response and four had stable disease) [59]. In addition to the immune checkpoint inhibitor, 
NK cell, T cell, and dendritic cell-based therapies have been tried to treat cholangiocarci-
noma. In the future, immunotherapy might be a new treatment option of biliary cancer 
treatment.
5.4. Ongoing clinical trials
Although there are no clear results yet, efforts to find new effective chemotherapy regimen 
for cholangiocarcinoma are continuing. There are several interesting ongoing clinical trials of 
chemotherapy for cholangiocarcinoma.
For the first-line chemotherapy for advanced cholangiocarcinoma, a phase III study compar-
ing gemcitabine plus cisplatin/S1 combination to gemcitabine plus cisplatin combination is 
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under investigation (NCT02182778). For the second-line chemotherapy for advanced disease, 
a phase III trial of mFOLFOX regimen comparing to the best supportive care is ongoing (ABC-
06 study, NCT01926236), and another phase III trial is trying capecitabine with varlitinib, 
an inhibitor of tyrosine kinases—EGFR, HER2, and HER4—compared to capecitabine alone 
(TreeTopp study, NCT03093870), Also, there is a phase III trial of adjuvant chemotherapy after 
curative resection with gemcitabine and cisplatin compared to observation alone (ACTICCA-1 
trial, NCT02170090).
In addition to these phase III trials, various phase II/phase II trials are underway and expected 
to report encouraging results in the near future.
5.5. Other challenges
Overcoming disease heterogeneity is another important issue for physicians and research-
ers. As we discussed, biliary tract cancers have many subgroups according to anatomy and 
molecular features. In addition to relative rarity of cholangiocarcinoma, this heterogeneity 
has made clinical trials be small size and segmental. It is very difficult to draw integrated 
results from individual studies due to these heterogeneity characteristics of cholangio-
carcinoma. In the future, it will be necessary to carry out multicenter and international 
cooperation to conduct large-scale clinical trials with subgroups sharing homogeneous 
characteristics.
Sample acquisition is one of the challenging tasks in pancreatobiliary tumor. If the future 
of technology including artificial intelligence allows us to perform more accurate sample 
acquisition technics or on-site mutation analyses easily, there will be significant benefits for 
diagnosis and treatment for these fatal diseases. And, established preclinical models need to 
identify new biomarkers and predict treatment response to chemotherapy. In addition to ani-
mal model, in vitro humanlike cell culture methods, such as organoid model or conditionally 
reprogrammed cell culture, are now being actively studied. These efforts will lead us to the 
era of precision medicine.
6. Summary and conclusion
Cholangiocarcinoma is a rare malignant tumor that originates from the epithelial cells of the 
bile duct system. While only surgical resection can provide a cure, most of cholangiocarcino-
mas are detected at inoperable stage and associated with poor prognosis. Moreover, cholan-
giocarcinoma has high recurrence rate, even after curative surgery.
Adjuvant chemotherapy is effective in patients with cholangiocarcinoma after curative sur-
gery, especially with lymph node-positive and resection margin-positive disease. Although 
there are limited clinical trial data to establish a standard chemotherapy regimen for cholan-
giocarcinoma after surgery, current recommended regimens are fluoropyrimidine-based or 
gemcitabine-based chemotherapies.
Palliative chemotherapy has an important role in the treatment of advanced and recur-
rent cholangiocarcinoma. According to the results of randomized controlled phase III trial, 
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gemcitabine plus cisplatin combination became the standard treatment option for first-line 
chemotherapy of advanced and metastatic cholangiocarcinoma. Gemcitabine-based or fluoro-
pyrimidine-based combination chemotherapies can be other options. The efficacy of second-
line chemotherapy is not definite until now.
Precision medicine is noticed in recent periods in addition to cytotoxic systemic chemother-
apy or chemoradiation. Identify novel therapeutic targets based on next-generation sequenc-
ing technology, and immunologic assessment is actively taking place. In the future, anticancer 
therapy of cholangiocarcinoma will develop to identify specific genes expressed in individual 
patients and provide personalized therapies accordingly.
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